Abstract
Background Bangladesh is going through an unprecedented crisis since the onset of the COVID-19 pandemic. Throughout the COVID-19 pandemic, the reproduction number of COVID-19 swarmed in the scientific community and public media due to its simplicity in explaining an infectious disease dynamic. This paper aims to estimate the effective reproduction number (Rt) for COVID-19 over time in Bangladesh and its districts using reported cases.
Methods Adapted methods derived from Bettencourt and Ribeiro (2008), which is a sequential Bayesian approach using the compartmental Susceptible-Infectious-Recovered (SIR) model, have been used to estimate Rt.
Results As of July 21, the mean Rt is 1.32(0.98-1.70, 90% HDI), with a median of 1.16(0.99-1.34 90% HDI). The initial Rt of Bangladesh was 3, whereas the Rt on the day of imposing nation-wide lockdown was 1.47, at the end of lockdown phase 1 was 1.06, at the end of lockdown phase 2 was 1.33. Each phase of nation-wide lockdown has contributed to the decline of effective reproduction number (Rt) for Bangladesh by 28.44%, and 26.70%, respectively, implying moderate effectiveness of the epidemic response strategies.
Interpretation and Conclusion The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh. The Rt continued to fall below the threshold value one steadily from the beginning of July and sustained around 1. The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh. As of July 21, the current estimate of Rt is 1.07(0.92-1.15: 90% HDI), meaning that an infected individual is spreading the virus to an average of one other, with 0.07 added chance of infecting a second individual. This whole research recommends two things- broader testing and careful calibration of measures to keep Rt a long way below the crucial threshold one.
Highlights
As of July 21, the mean Rt and growth factor is 1.32 and 1.02, respectively.
Each phase of nation-wide lockdown has contributed to the decline of effective reproduction number (Rt) for Bangladesh by 28.44%, and 26.70%, respectively, implying moderate effectiveness of the epidemic response strategies.
The Rt of Bangladesh was below 1 for only 20 days, which was observed during May 24- 25, June 19-21, from June 30 to July 6, July 9-12, and July 16-19,2020.
The initial Rt of Bangladesh was 3, whereas the Rt on the day of imposing nation-wide lockdown was 1.47, at the end of lockdown phase-1 was 1.06, at the end of lockdown phase-2 was 1.33.
The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh.
The Rt continued to fall below the threshold value one steadily from the beginning of July and sustained around one.
We suspect that a low testing rate may influence the constant decline of Rt below threshold value 1 in the course of July.
The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh.
As of July 21, the current estimate of Rt is 1.07(0.92-1.15: 90% HDI), meaning that an infected individual is spreading the virus to an average of one other, with 0.07 added chance of infecting a second individual.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Authors did not receive any fund for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data were collected from public database and are with the corresponding author. Data will be available on a valid request.
